Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs Glimepiride in Type 2 Diabetes
NCT01404676Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2010
- Primary completion
- May 2012
- Countries
- 1
- Sponsor
- Samsung Medical Center
- Modality
- Small Molecules
- Drugs
- vildagliptin
- Conditions
- type 2 diabetes mellitus (T2DM)
01
Overview
Phase 4, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Samsung Medical Center. Primary endpoint: Mean Amplitude of Glycemic Excursion at 12 weeks. Started Jun 2010; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Type 2 diabetic patients with HbA1c levels between 7% and 10% who are currently being treated with metformin.
04
Endpoints
Primary
Mean Amplitude of Glycemic Excursion
Beyond the preview
Go deeper on NCT01404676.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01404676.